Page 5,719«..1020..5,7185,7195,7205,721..5,7305,740..»

ISCI Announces Global Physician Network

Posted: Published on February 12th, 2013

PITTSTON, ME--(Marketwire - Feb 12, 2013) - YaFarm Technologies, Inc. ( PINKSHEETS : YFRM ) (YaFarm, or the Company) announced todaythatThe Integrative Stem Cell Institute (ISCI), apremier provider of point-of-care, stem cell-based therapies, has launched a global physician's network, to connect international patients to local physicians, and to link physicians to opportunities for education, training and collaboration in regenerative medicine. ISCI has formed The International Stem Cell Practice (ISCP) to meet two very specific needs in the field of stem cell medicine: physician education and patient follow up. With the creation of this global network, the ISCI hopes to provide a highly scalable and versatile solution to serve the needs of both of these crucial audiences. Working with a state-of-the art laboratory and a fully integrative medical facility in Cancun, Mexico, the ISCI and the ISCP will provide a venue for hands-on training in regenerative medicine as well as educational opportunities for physicians to exchange best practices and explore emerging trends in the field. The ISCP will also be hosting a series of regional meetings throughout the United States and Latin America to foster professional collaboration. The main focus of the network, however, will be providing initial evaluation and long-term … Continue reading →

Posted in Cell Medicine | Comments Off on ISCI Announces Global Physician Network

Mouse model improves understanding of clear cell sarcoma

Posted: Published on February 12th, 2013

Feb. 11, 2013 Geneticists led by University of Utah Nobel Prize Laureate Mario R. Capecchi, Ph.D., have engineered mice that develop clear cell sarcoma (CCS), a significant step in better understanding how this rare and deadly soft tissue cancer arises. The mouse model also can potentially speed the development of drugs to target genes that must be activated for the cancer to form. CCS arises in connective soft tissues, such as tendons, fat, blood vessels, and muscle. Researchers have known that the first step in the process that leads to CCS occurs when two human chromosomes, 12 and 22, randomly break after DNA gets damaged from the effects of sunlight or other causes. Each chromosome usually harmlessly rejoins after breaking. But occasionally part of one chromosome will join with part of the other to create a new gene called a fusion gene. When this gene, ews-atf1 is generated, it initiates the process that causes CCS. The rare and aggressive nature of sarcomas, and their occurrence in children and young adults, long has interested Capecchi. In a study in the Feb. 11, 2013, online edition of Cancer Cell, he and colleagues from the University of Utah, the University of Texas M.D. … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on Mouse model improves understanding of clear cell sarcoma

A Microscopic View of the Stem-Cells Industry

Posted: Published on February 12th, 2013

Fearing that unscrupulous use may hijack this promising field, stakeholders are racing to regulate its applications. Are they swift enough? Image: Mallikarjun Katakol for Forbes India Stempeutics Researchs CEO BN Manohar: While we work till science matures, others [stem -cells clinics] are making money from day one We dont do clinical trials, we provide commercial stem-cell therapy, says an executive of a Pune-based company on the phone when we inquire about participating in one to avail the treatment that its website boldly speaks of. If you cant come in person, send us your case study in email and well advise you how many infusions of stem cells your patient would require, he suggests. The companys website says it has provided 1,000 infusions to patients and is a leader in stem-cells therapy. The so-called therapy costs upwards of Rs 2-3 lakh, the executive discloses on persuasion. This Pune clinic is only one among the many that peddle the unproven stem-cell therapy. They are supposed to enrol patients under a proper clinical trial; instead they get by with merely adding the word experimental to their offerings. You wont find these clinics on the clinical trial registry of the Indian Council of Medical … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on A Microscopic View of the Stem-Cells Industry

Synageva BioPharma™ Initiates Dosing in Phase 3 Trial of Sebelipase Alfa in Children and Adults with Late Onset LAL …

Posted: Published on February 11th, 2013

LEXINGTON, Mass.--(BUSINESS WIRE)-- Synageva BioPharma Corp. (Synageva) (GEVA), a clinical stage biopharmaceutical company developing therapeutic products for rare diseases, today announced that the first patient initiated treatment in the ARISE trial (Acid Lipase Replacement Investigating Safety and Efficacy), a global, Phase 3, randomized, double-blind, placebo-controlled study of sebelipase alfa in children and adults with late onset lysosomal acid lipase deficiency (LAL Deficiency). The buildup of abnormal fats in LAL Deficiency can cause progressive and severe liver damage including cirrhosis in children and adults, as well as accelerated atherosclerosis, said Anthony Quinn, MBChB, PhD, FRCP, Senior Vice President and Chief Medical Officer at Synageva. By replacing the deficient enzyme that causes the accumulation of these abnormal fats, sebelipase alfa addresses the root cause of LAL Deficiency. Based on data from the previously conducted preclinical and clinical studies with sebelipase alfa, the Phase 3 ARISE trial was designed to assess the effects of sebelipase alfa on a broad range of abnormalities associated with LAL Deficiency. About ARISE: A global Phase 3 trial of sebelipase alfa in children and adults with late onset LAL Deficiency The ARISE trial will enroll 50 patients (children and adults) with late onset LAL Deficiency. Patients enrolled in … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on Synageva BioPharma™ Initiates Dosing in Phase 3 Trial of Sebelipase Alfa in Children and Adults with Late Onset LAL …

Celldex Announces Upcoming Oral Presentation on CDX-301 at the American Society for Blood and Marrow Transplantation …

Posted: Published on February 11th, 2013

NEEDHAM, Mass., Feb. 11, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (CLDX) today announced that Michael Yellin, MD, Vice President of Clinical Science, will present final results from a Phase 1 trial of CDX-301 (rhuFlt3L) in healthy volunteers in an oral presentation at the American Society for Blood and Marrow Transplantation 2013 BMT Tandem Meetings. The presentation will be held on Wednesday, February 13, 2013 at 4:45 pm MST (6:45 pm EST) at the Salt Palace Convention Center in Salt Lake City, Utah. The Company will issue a press release outlining the results of the presentation before market open on Thursday, February 14, 2013. The Company previously announced that it plans to initiate a pilot study in hematopoietic stem cell transplant by year end 2013. CDX-301 or Flt3L is a potent cytokine that stimulates the expansion and differentiation of hematopoietic progenitor and stem cells. Flt3L has demonstrated a unique capacity to increase the number of circulating dendritic cells in both laboratory and clinical studies. In addition, Flt3L has shown impressive results in models of cancer, infectious diseases and inflammatory/autoimmune diseases. Celldex believes this ligand may hold significant opportunity for synergistic development in combination with other molecules. About Celldex Therapeutics, Inc. … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on Celldex Announces Upcoming Oral Presentation on CDX-301 at the American Society for Blood and Marrow Transplantation …

Plunkett's Biotech & Genetics Industry Trends & Statistics 2013: A Summary Version of Plunkett's Biotech & Genetics …

Posted: Published on February 11th, 2013

NEW YORK, Feb. 11, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Plunkett's Biotech & Genetics Industry Trends & Statistics 2013: A Summary Version of Plunkett's Biotech & Genetics Industry Almanac 2013 http://www.reportlinker.com/p01054189/Plunketts-Biotech--Genetics-Industry-Trends--Statistics-2013-A-Summary-Version-of-Plunketts-Biotech--Genetics-Industry-Almanac-2013.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Genomics Key Features: -Industry trends analysis, market data and competitive intelligence-Market forecasts and Industry Statistics-Buyer may register for access to search and export data at Plunkett Research Online Pages: 77 Statistical Tables Provided: 18 Geographic Focus: Global A condensed market research report excerpted from Plunkett's Biotech & Genetics Industry Almanac 2013, including forecasts and market estimates, technologies analysis and vital statistical tables. You will gain significant insights that can help you shape your own strategy for business development, product development and investments. -How is the industry evolving? -How is the industry being shaped by new technologies? -How is demand growing in emerging markets and mature economies?-What is the size of the market now and in the future? Contents, Statistics, Forecasts and Analysis Include: Follow this link: Plunkett's Biotech & Genetics Industry Trends & Statistics 2013: A Summary Version of Plunkett's Biotech & Genetics ... … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on Plunkett's Biotech & Genetics Industry Trends & Statistics 2013: A Summary Version of Plunkett's Biotech & Genetics …

ACT’s Clinical Partner Receives FDA Approval to Initiate Clinical Trial Using the Company’s hESC-derived Cells to …

Posted: Published on February 11th, 2013

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Advanced Cell Technology, Inc.s (ACT; OTCBB: ACTC or the Company), clinical partner, the University of California, Los Angeles (UCLA), has received approval of its Investigator Investigational New Drug (IND) Application with the US Food and Drug Administration (FDA), led by Steven Schwartz, M.D., Ahmanson Professor of Ophthalmology at the David Geffen School of Medicine at UCLA and retina division chief at UCLA's Jules Stein Eye Institute, to initiate a Phase I/II study using ACTs retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs) to treat myopic macular degeneration (MMD, or myopia), commonly known as nearsightedness. The primary focus of the study will be to evaluate the safety in patients with severe myopia of the type that causes fissures in the RPE layer of the eye. Dr. Schwartz is the principal investigator in each of ACTs two Phase I/II clinical trials for Stargardt's macular dystrophy and dry age-related macular degeneration (dry AMD) using RPE cells derived from hESCs. The approval was announced by Dr. Schwartz in his presentation at Bascom Palmer Eye Institutes tenth annual angiogenesis meeting, Angiogenesis, Exudation, and Degeneration 2013, on Saturday, February 9 in Miami, Fla. We are encouraged by Dr. Schwartzs … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on ACT’s Clinical Partner Receives FDA Approval to Initiate Clinical Trial Using the Company’s hESC-derived Cells to …

Cytomedix Announces Approval of Angel cPRP System in Australia

Posted: Published on February 11th, 2013

GAITHERSBURG, MD--(Marketwire - Feb 11, 2013) - Cytomedix, Inc. ( OTCQX : CMXI ) (the "Company"), a regenerative therapies company commercializing and developing innovative platelet and adult stem cell technologies, announced today that its Angel cPRP System has been listed by the TGA (Therapeutic Goods Administration) in Australia. Angel will be marketed and distributed by Medtel, a leading supplier of medical equipment and devices in Australia. Australia is the latest international territory where the Angel System is now included and available for sale. The Angel is also on the market in various countries throughout Europe and the Middle East. Cytomedix has established a broad network of experienced distributors to promote and sell the product in international markets. Further territory launches are expected in 2013. "We are pleased to launch Angel in Australia where there is significant growth potential for PRP," said Martin Rosendale, Chief Executive Officer of Cytomedix. "Sales in international markets are a meaningful contributor to overall Angel revenues, and are growing at an encouraging rate. We are fortunate to be working with Medtel as they have an excellent track record in launching and promoting innovative healthcare technology products." Jeannie Devereaux, Business Development Manager, Regenerative Medicine Sports, Orthopedic & … Continue reading →

Posted in Stem Cell Human Trials | Comments Off on Cytomedix Announces Approval of Angel cPRP System in Australia

LifeMap Sciences, a Subsidiary of BioTime, Reports Its Databases Currently Utilized by an Estimated Two Million Unique …

Posted: Published on February 11th, 2013

ALAMEDA, Calif.--(BUSINESS WIRE)-- LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT:BTX), announced today that according to Google Analytics, the Companys databases have attracted over two million unique visitors in the previous 12 months. Since the announcement of the acquisition of Xennex in May 2012, LifeMap launched LifeMap Discovery, a database resource for stem cell research, and MalaCards, a database with nearly 17,000 human disease entries. These assets, combined with GeneCards, a compendium of human genes, provide an integrated database suite with diverse commercial opportunities in science and medicine. LifeMap Sciences holds the exclusive worldwide license to market GeneCards and MalaCards from Yeda Research and Development Company Ltd., the commercial arm of the Weizmann Institute of Science. LifeMap Discovery is a database owned and developed by LifeMap Sciences. In this update, LifeMap describes the nature of its current users, and outlines for the first time its goals for 2013 in marketing products to this user base. According to Google Analytics, the sites have generated more than 2,000,000 unique visitors with more than 13,000,000 page views in the past 12 months. LifeMap clients and partners include dozens of large, fee-paying pharmaceutical and biotechnology companies, as well as leading government patent … Continue reading →

Posted in Stem Cell Human Trials | Comments Off on LifeMap Sciences, a Subsidiary of BioTime, Reports Its Databases Currently Utilized by an Estimated Two Million Unique …

Stem cell breakthrough could lead to new bone repair therapies on nanoscale surfaces

Posted: Published on February 11th, 2013

Feb. 11, 2013 Scientists at the University of Southampton have created a new method to generate bone cells which could lead to revolutionary bone repair therapies for people with bone fractures or those who need hip replacement surgery due to osteoporosis and osteoarthritis. The research, carried out by Dr Emmajayne Kingham at the University of Southampton in collaboration with the University of Glasgow and published in the journal Small, cultured human embryonic stem cells on to the surface of plastic materials and assessed their ability to change. Scientists were able to use the nanotopographical patterns on the biomedical plastic to manipulate human embryonic stem cells towards bone cells. This was done without any chemical enhancement. The materials, including the biomedical implantable material polycarbonate plastic, which is a versatile plastic used in things from bullet proof windows to CDs, offer an accessible and cheaper way of culturing human embryonic stem cells and presents new opportunities for future medical research in this area. Professor Richard Oreffo, who led the University of Southampton team, explains: "To generate bone cells for regenerative medicine and further medical research remains a significant challenge. However we have found that by harnessing surface technologies that allow the generation … Continue reading →

Comments Off on Stem cell breakthrough could lead to new bone repair therapies on nanoscale surfaces

Page 5,719«..1020..5,7185,7195,7205,721..5,7305,740..»